Publication:
Cryotherapy for low risk prostate cancer, oncological and functional medium term outcomes: A three center prospective study

dc.contributor.authorŞENER, TARIK EMRE
dc.contributor.authorsLucan, Valerian Ciprian; Lugnani, Franco; Buttice, Salvatore; Sener, Emre; Netsch, Christopher; Talso, Michele; Cantiello, Francesco; Pappalardo, Rosa; Magno, Carlo
dc.date.accessioned2022-03-14T08:26:30Z
dc.date.accessioned2026-01-10T18:58:45Z
dc.date.available2022-03-14T08:26:30Z
dc.date.issued2017-06-30
dc.description.abstractObjectives: Analyze the oncologic and functional outcomes in patients affected by low risk prostate cancer underwent prostate cryotherapy. Materiasl and methods: It's a prospective tricentric study of 434 patients treated with prostate cryoablation for low risk prostate cancer. By low risk we refer to the D'Amico's risk classification. Two cycles of freezing/thawing are run for each patient following the technique described by Onik. Results: For the 434 patients, the median age was 66 years with a standard deviation of +/- 6.68, the average PSA was 6.17 ng/d/L, the median 5.55 with a standard deviation of +/- 2.13, the mean prostate volume was 35.59 cc, the median 34.00 cc, with a standard deviation of +/- 7.89. Biochemical failure occurred in 67 patients (15.4%). Pre-operative erectile function in men was distributed as follows: severe in 95 patients (19.2%), moderate in 95 (19.2%), medium-moderate in 180 (36.4%), mild in 92 (18.6%), with no dysfunction in 32 (6.5%) patients. Post-operative erectile function, measured 1 month after cryotherapy, was distributed as follows: severe in 321 (65%) patients, moderate in 69 (14%), medium-moderate in 79 (16%), mild in 23 (4.7%), and no dysfunction in only 2 patients (0.4%). Post-operative erectile function after 3 months was distributed as follows: severe in 233 (47.2%) patients, moderate in 66 (13.4%), medium-moderate in 122 (24.7%), mild in 65 (13.2%), and no dysfunction in 8 patients (1.6%). Urinary incontinence was present in 21 patients (4.8%) after 3 months while it dropped to 13 patients (2.9%) after 6 months. Conclusions: Cryotherapy in the treatment of prostate cancer remains a viable alternative. The availability of new cry-oprobes and the use of new diagnostic means such as fusion magnetic resonance will make this more precise and more effective method.
dc.identifier.doi10.4081/aiua.2017.2.97
dc.identifier.eissn2282-4197
dc.identifier.issn1124-3562
dc.identifier.pubmed28679177
dc.identifier.urihttps://hdl.handle.net/11424/241786
dc.identifier.wosWOS:000406054200002
dc.language.isoeng
dc.publisherPAGEPRESS PUBL
dc.relation.ispartofARCHIVIO ITALIANO DI UROLOGIA E ANDROLOGIA
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectProstate cryotherapy
dc.subjectMinimally invasive treatment
dc.subjectFocal therapy
dc.subjectLow risk prostate cancer
dc.subjectACTIVE SURVEILLANCE
dc.subjectRADICAL PROSTATECTOMY
dc.subjectRADIATION-THERAPY
dc.subjectCRYOSURGERY
dc.subjectSURVIVAL
dc.subjectTRIAL
dc.subjectMEN
dc.titleCryotherapy for low risk prostate cancer, oncological and functional medium term outcomes: A three center prospective study
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage101
oaire.citation.issue2
oaire.citation.startPage97
oaire.citation.titleARCHIVIO ITALIANO DI UROLOGIA E ANDROLOGIA
oaire.citation.volume89

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
file.pdf
Size:
690.85 KB
Format:
Adobe Portable Document Format